Drugpatentwatch – skyrizi biologic patent analysis?

I can help with that, but I need one quick clarification first:

Do you want (A) a general “Skyrizi patent landscape” overview, or (B) a specific “DrugPatentWatch-style” breakdown (e.g., listing each relevant patent number, assignee, key claims/molecules, expiration dates, and what portions cover method of use vs. formulation vs. manufacturing)?

Also, tell me the country/market you care about (typically US, EU, UK, CA). Patent coverage is very jurisdiction-specific.

While you confirm, here’s the high-level context for Skyrizi (risankizumab-rzaa)

Skyrizi is a monoclonal antibody (anti–IL-23 p19) used for inflammatory conditions (notably psoriasis and psoriatic arthritis, and other indications in some geographies).

A “patent analysis” for a biologic usually focuses on:

1. Composition-of-matter / antibody-specific patents
   • The early foundational patents on the antibody/sequence.
2. Formulation / process patents
   • Manufacturing process, purification, formulation (buffers, excipients, lyophilization vs. liquid).
3. Method-of-use patents
   • Specific clinical indications, dosing regimens, patient populations, or combination therapies.
4. Exclusivity & regulatory exclusivities (not just patents)
   • In the US especially: BPCIA exclusivity (reference product exclusivity / interchangeable exclusivity—depending on program and timing) and any pediatric exclusivity (if applicable).
5. Biosimilar vs. “interchangeable” pathways
   • Biosimilar development generally relies on showing similarity and can be constrained by the list of patents and exclusivity.

What I can produce for you (pick one)

1. Market-focused summary (e.g., “When would biosimilars potentially enter US/EU considering patents + exclusivity?”)
2. Patent-by-patent table (patent #, type, claims/coverage summary, jurisdiction, expected expiry)
3. Freedom-to-operate style checklist (what’s most likely to block biosimilar approval and what might be “workarounds”)
4. Biosimilar landscape scan (which companies are/aren’t active in each market, and the likely target patents)

To proceed, reply with:

• Jurisdiction(s): US / EU / UK / CA / other?
• Indication(s): psoriasis only, or also psoriatic arthritis, Crohn’s, etc.?
• Output format: brief summary or detailed patent table?

If you want, paste the DrugPatentWatch link(s) you’re looking at (or the patent list you see there), and I’ll turn it into a clean, understandable analysis and highlight which patents are most likely to be blocking vs. peripheral.